Database : MEDLINE
Search on : Babesiosis [Words]
References found : 4257 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 426 go to page                         

  1 / 4257 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29524239
[Au] Autor:Sayama Y; Zamoto-Niikura A; Matsumoto C; Saijo M; Ishihara C; Matsubayashi K; Nagai T; Satake M
[Ad] Address:Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, National Institute of Infectious Diseases, Tokyo, Japan.
[Ti] Title:Analysis of antigen-antibody cross-reactivity among lineages and sublineages of Babesia microti parasites using human babesiosis specimens.
[So] Source:Transfusion;, 2018 Mar 09.
[Is] ISSN:1537-2995
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Human babesiosis is caused mainly by Babesia microti and has recently become a public health concern due to an increase in transfusion-transmitted infection. Thus, the development of an antibody detection method with high specificity and sensitivity is a priority. Seroreactivity against B. microti has been reported to be highly specific not only to B. microti lineages but also to sublineages. This study aimed to elucidate the human antibody reactivity against various lineages, including US, Kobe, and Hobetsu, and sublineages (North America and East Asia) in the US lineage. STUDY DESIGN AND METHODS: Twenty samples obtained from individuals infected with B. microti in the United States were tested for the presence of anti-B. microti antibodies using indirect immunofluorescence assay (IFA) and Western blotting (WB) to indicate antigens of each (sub-)lineage. RESULTS: By IFA, 20 samples showed reactivity to the North America sublineage (titer range, 64-4096), 16 to the East Asia sublineage (64-512), 10 to the Kobe (64-128), and five to the Hobetsu (64). Antibody titers to the East Asia sublineage, Kobe, and Hobetsu were significantly lower than those to the North America sublineage (p < 0.01). By WB, in parallel with the IFA results, 18 samples showed strong reactions to the North America sublineage, weak reactions to the East Asia sublineage, and near-zero reactions to the Kobe and Hobetsu. CONCLUSION: Human antibodies induced by B. microti infection are highly specific against B. microti lineages and sublineages with low cross-reactivity. Developing a precise antibody detection method may require specific antigens based on B. microti lineages and sublineages.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1111/trf.14558

  2 / 4257 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29394381
[Au] Autor:Stahl P; Poinsignon Y; Pouedras P; Ciubotaru V; Berry L; Emu B; Krause PJ; Ben Mamoun C; Cornillot E
[Ad] Address:Institute of Virology, Parasitology Unit, University of Marburg, Marburg, Germany.
[Ti] Title:Case report of the patient source of the Babesia microti R1 reference strain and implications for travelers.
[So] Source:J Travel Med;25(1), 2018 Jan 01.
[Is] ISSN:1708-8305
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Background: In 2002, a previously healthy 69-year-old man travelled to France from the United States and presented to our hospital with a febrile illness that subsequently was determined to be babesiosis. The blood isolated from this patient served as a source for propagation of the Babesia microti R1 strain with subsequent sequencing and annotation of the parasite genome. Methods: Upon admission, we obtained a medical history, performed a physical examination, and examined his blood for the presence of a blood borne pathogen by microscopy, PCR and indirect immunofluorescence antibody testing. Once the diagnosis of babesiosis was made, we reviewed the literature to assess the distribution of B. microti-associated babesiosis cases in immunocompetent patients from outside the USA. Results: The patient recalled a tick bite during the previous month on Cape Cod, Massachusetts. The diagnosis was confirmed by identification of Babesia-infected red blood cells on blood smears, amplification of B. microti DNA in blood by PCR and the presence of B. microti antibody in the serum. This strain was the first isolate of B. microti to be fully sequenced and its annotated genome serves as a reference for molecular and cell biology studies aimed at understanding B. microti pathophysiology and developing diagnostic tests and therapies. A review of babesiosis cases demonstrates a worldwide distribution of B. microti and identifies potential emerging endemic areas where travelers may be at risk of contracting B. microti infection. Conclusion: This case provides clinical information about the patient infected with the R1 isolate and a review of travel risk, diagnosis and treatment of babesiosis in endemic and non-endemic areas.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.1093/jtm/tax073

  3 / 4257 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29272385
[Au] Autor:Kingry LC; Anacker M; Pritt B; Bjork J; Respicio-Kingry L; Liu G; Sheldon S; Boxrud D; Strain A; Oatman S; Berry J; Sloan L; Mead P; Neitzel D; Kugeler KJ; Petersen JM
[Ad] Address:Centers for Disease Control and Prevention, Division of Vector-Borne Diseases, Fort Collins, CO.
[Ti] Title:Surveillance for and Discovery of Borrelia Species in US Patients Suspected of Tickborne Illness.
[So] Source:Clin Infect Dis;, 2017 Dec 20.
[Is] ISSN:1537-6591
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Background: Tick-transmitted Borrelia species fall into two heterogeneous bacterial complexes comprised of multiple species, the relapsing fever (RF) group and the Borrelia burgdorferi sensu lato group, which are the causative agents of Lyme borreliosis (LB), the most common tickborne disease in the northern hemisphere. Geographic expansion of human LB in the United States and discovery of emerging Borrelia pathogens underscores the importance of surveillance for disease causing Borrelia. Methods: De-identified clinical specimens, submitted by providers throughout the United States, for patients suspected of LB, anaplasmosis, ehrlichiosis, or babesiosis, were screened using a Borrelia genus level TaqMan PCR. Borrelia species and sequence types (STs) were characterized by multi-locus sequence typing (MLST) utilizing next generation sequencing. Results: Among the 7,292 tested specimens tested, five different Borrelia species were identified: two causing LB, B. burgdorferi (n=25) and B. mayonii (n=9), and three RF borreliae, B. hermsii (n=1), B. miyamotoi (n=8), and CandidatusB. johnsonii (n=1), a species previously detected only in the bat tick, Carios kelleyi. ST diversity was greatest for B. burgdorferi positive specimens, with new STs identified primarily among synovial fluids. Conclusion: These results demonstrate broad PCR screening followed by MLST is a powerful surveillance tool for uncovering the spectrum of Borrelia species causing human disease, improving understanding of their geographic distribution, and investigating the correlation between B. burgdorferi STs and joint involvement. Detection of CandidatusB. johnsonii in a patient with suspected tickborne disease suggests this species may be a previously undetected cause of illness in humans with exposure to bat ticks.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1093/cid/cix1107

  4 / 4257 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29274217
[Au] Autor:Szymczak J; Kozlowska J; Doligalska M
[Ad] Address:Department of Parasitology, Faculty of Biology, University of Warsaw, ul. Miecznikowa 1, 02-096 Warsaw, Poland
[Ti] Title:Evaluation of inhibitory effect of redox-active antimalarial drug against Babesia microti in mice
[So] Source:Ann Parasitol;63(3):223­227, 2017.
[Is] ISSN:2299-0631
[Cp] Country of publication:Poland
[La] Language:eng
[Ab] Abstract:Babesiosis is an emerging, tick-transmitted disease caused by the intraerythrocytic parasite Babesia microti. In immunocompetent individuals, B. microti infection quickly resolves after antibabesial treatment. Immunocompromised patients and those of advanced age experience chronic and relapsing babesiosis, accompanied by severe complications and often, a fatal outcome. In these individuals, B. microti infection may persist despite multiple courses of treatment with antiprotozoal drugs. The increasing incidence of human babesiosis caused by B. microti, coupled with a growing number of immunosuppressed people who do not respond to standard antibabesial therapy, emphasises the need for new therapeutics for this protozoan infection with more effective mechanisms of action. Plasmodione, namely 3-[4-(trifluoromethyl)benzyl]-menadione, acts as a redox cycler and disrupts the redox homeostasis of Plasmodium-infected erythrocytes. The present study was designed to evaluate the potential inhibitory effect of this novel antimalarial compound against intraerythrocytic stages of B. microti in mice. Our results demonstrate that plasmodione did not reduce the level of parasitemia in B. microti-infected mice, indicating that interfering with the parasite redox balance is not an effective strategy to restrict the division of this protozoan. The mechanism of parasite resistance to plasmodione may be based on the differences in the oxidative metabolisms of Babesia and Plasmodium parasites inside infected erythrocytes. The significance of our results is discussed in relation to the development of novel antibabesial drugs based on redox-active benzylmenadiones.
[Mh] MeSH terms primary: Antimalarials/therapeutic use
Babesia microti
Babesiosis/drug therapy
Vitamin K 3/analogs & derivatives
[Mh] MeSH terms secundary: Animals
Antimalarials/pharmacology
Babesiosis/parasitology
Mice
Oxidation-Reduction
Vitamin K 3/therapeutic use
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (3-(4-(trifluoromethyl)benzyl)menadione); 0 (Antimalarials); 723JX6CXY5 (Vitamin K 3)
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Js] Journal subset:IM
[Da] Date of entry for processing:171224
[St] Status:MEDLINE
[do] DOI:10.17420/ap6303.109

  5 / 4257 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29415034
[Au] Autor:Csordas BG; Cunha RC; Garcia MV; da Silva SS; Leite FL; Andreotti R
[Ad] Address:Programa de Pós-graduação em Doenças Infecciosas e Parasitárias, Faculdade de Medicina, Universidade Federal de Mato Grosso do Sul, Bolsista de Doutorado pela Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Campo Grande, Mato Grosso do Sul, Brasil.
[Ti] Title:Molecular characterization of the recombinant protein RmLTI-BmCG-LTB: Protective immunity against Rhipicephalus (Boophilus) microplus.
[So] Source:PLoS One;13(2):e0191596, 2018.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The bovine tick Rhipicephalus (Boophilus) microplus is found in several tropical and subtropical regions of the world. This parasite transmits pathogens that cause disease, such as babesiosis (Babesia bovis and B. bigemina) and anaplasmosis (Anaplasma marginale). Tick infestations cause enormous livestock losses, and controlling tick infestations and the transmission of tick-borne diseases remains a challenge for the livestock industry. Because the currently available commercial vaccines offer only partial protection against R. (B.) microplus, there is a need for more efficient vaccines. Several recombinant antigens have been evaluated using different immunization strategies, and they show great promise. This work describes the construction and immunological characterization of a multi-antigen chimera composed of two R. (B.) microplus antigens (RmLTI and BmCG) and one Escherichia coli antigen (B subunit, LTB). The immunogenic regions of each antigen were selected and combined to encode a single polypeptide. The gene was cloned and expressed in E. coli. For all of the experiments, two groups (treated and control) of four Angus heifers (3-6 months old) were used. The inoculation was performed via intramuscular injection with 200 µg of purified recombinant chimeric protein and adjuvated. The chimeric protein was recognized by specific antibodies against each subunit and by sera from cattle inoculated with the chimera. Immunization of RmLTI-BmCG-LTB cattle reduced the number of adult female ticks by 6.29% and vaccination of cattle with the chimeric antigen provided 55.6% efficacy against R. (B.) microplus infestation. The results of this study indicate that the novel chimeric protein is a potential candidate for the future development of a more effective vaccine against R. (B.) microplus.
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1802
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[St] Status:In-Process
[do] DOI:10.1371/journal.pone.0191596

  6 / 4257 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28453188
[Au] Autor:Moritz ED; Tonnetti L; Hewins ME; Berardi VP; Dodd RY; Stramer SL
[Ad] Address:Scientific Affairs Department, American Red Cross, Gaithersburg, Maryland.
[Ti] Title:Description of 15 DNA-positive and antibody-negative "window-period" blood donations identified during prospective screening for Babesia microti.
[So] Source:Transfusion;57(7):1781-1786, 2017 07.
[Is] ISSN:1537-2995
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Blood donation screening detecting only antibodies fails to identify donors in the earliest stage of infection, before a detectable immunologic response, that is, the "window period" (WP). We present data on WP donations identified during prospective screening for Babesia microti, a transfusion-transmissible parasite of increasing concern in the United States. STUDY DESIGN AND METHODS: Blood donations collected in Connecticut, Massachusetts, Minnesota, and Wisconsin were screened using polymerase chain reaction (PCR) and arrayed fluorescence immunoassay (AFIA) to detect B. microti DNA and antibodies, respectively. Parasite loads were estimated using quantitative PCR. Red blood cell (RBC) samples were inoculated into hamsters to assess infectivity. Donors screening reactive were indefinitely deferred, tested by supplemental methods, and followed to assess DNA and antibody clearance. Demographic data from WP donors (i.e., those screening PCR positive and AFIA negative) were compared to data from other positive donors. RESULTS: Of 220,479 donations screened from June 2012 to August 2016, a total of 700 were positive, of which 15 (2% of positive donations or 1 per 14,699 screened donations) were confirmed WP donations. The median estimated parasite load in WP donations was 350 parasites/mL, no different than AFIA-positive and PCR-positive donors. Parasite loads in RBC samples from WP units ranged from 14 to 11,022 parasites/mL; RBC samples from three of 10 (30%) WP donations infected hamsters. The mean age of WP donors was 48 years (range, 17-75 years); three (20%) were female. WP donor demographics did not differ significantly from demographics of other donors. CONCLUSIONS: We report one per 15,000 B. microti WP infections in blood donors in endemic areas, demonstrating the importance of nucleic acid testing to mitigate the risk of transfusion-transmitted babesiosis.
[Mh] MeSH terms primary: Antibodies, Protozoan/blood
Babesia microti/isolation & purification
Blood Donors
DNA, Protozoan/blood
[Mh] MeSH terms secundary: Adolescent
Adult
Aged
Babesia microti/genetics
Babesia microti/immunology
Female
Fluorescent Antibody Technique
Humans
Male
Middle Aged
Polymerase Chain Reaction
Prospective Studies
Young Adult
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Antibodies, Protozoan); 0 (DNA, Protozoan)
[Em] Entry month:1709
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Js] Journal subset:IM
[Da] Date of entry for processing:170429
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14103

  7 / 4257 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29499568
[Au] Autor:Guswanto A; Nugraha AB; Tuvshintulga B; Tayebwa DS; Rizk MA; Batiha GE; Gantuya S; Sivakumar T; Yokoyama N; Igarashi I
[Ad] Address:National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Nishi 2-13 Inada-cho, Obihiro 080-8555, Japan; Balai Veteriner Subang (DIC Subang), Jl. Terusan Garuda 33/11 Blok Werasari Dangdeur, Subang, Jawa Barat 41212, Indonesia. Electronic address: gu
[Ti] Title:17-DMAG inhibits the multiplication of several Babesia species and Theileria equi on in vitro cultures, and Babesia microti in mice.
[So] Source:Int J Parasitol Drugs Drug Resist;8(1):104-111, 2018 Feb 27.
[Is] ISSN:2211-3207
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Heat shock protein 90 (Hsp90) is a chaperone protein that stabilizes cells during stress or non-stress responses. Previous reports have shown that Hsp90 is a potential drug target to suppress the multiplication of several protozoan parasites. In this study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), an Hsp90 inhibitor, was evaluated for its inhibitory effect on five in vitro cultures of Babesia and Theileria species, including B. bovis, B. bigemina, B. divergens, B. caballi, and T. equi, and on the multiplication of a B. microti-infected mouse model. 17-DMAG showed the inhibitory effect in all of the species tested. The half maximum inhibition concentration (IC ) of 17-DMAG on B. bovis, B. bigemina, B. divergens, B. caballi, and T. equi was 77.6 ±â€¯2.9, 62.4 ±â€¯1.9, 183.8 ±â€¯3.2, 88.5 ±â€¯9.6, and 307.7 ±â€¯7.2 nM, respectively. The toxicity assay on MDBK and NIH/3T3 cell lines showed that 17-DMAG affected the viability of cells with an IC of 15.5 ±â€¯4 and 8.8 ±â€¯2 µM, respectively. Since the IC s were much lower on the parasites than on the host cell lines, the selectivity index were high for all tested species. Furthermore, the two-drug combination of 17-DMAG with diminazene aceturate (DA) and atovaquone (AV) showed synergism or addition on in vitro cultures of Babesia and Theileria parasites. In the mouse model, 17-DMAG at a concentration of 30 mg/kg BW effectively inhibited the multiplication of B. microti. Moreover, if combined with DA or AV, 17-DMAG showed a comparable inhibition at the half dose. Taken together, these results indicate that 17-DMAG is a potent drug for treating piroplamosis. The data warrant further evaluation of 17-DMAG as an antibabesial drug and as an option in combination with atovaquone for the treatment of human babesiosis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[St] Status:Publisher

  8 / 4257 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29496491
[Au] Autor:Asensi V; González LM; Fernández-Suárez J; Sevilla E; Navascués RÁ; Suárez ML; Lauret ME; Bernardo A; Carton JA; Montero E
[Ad] Address:Infectious Diseases Unit, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Oviedo, Spain.
[Ti] Title:A fatal case of Babesia divergens infection in Northwestern Spain.
[So] Source:Ticks Tick Borne Dis;, 2018 Feb 21.
[Is] ISSN:1877-9603
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:We describe a fatal case caused by the intra-erythrocytic Babesia divergens parasite in an elderly woman. This is the third case of fatal babesiosis reported in the last 15 years in Europe, and the only one in a patient with an intact spleen.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[St] Status:Publisher

  9 / 4257 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29227211
[Au] Autor:Karnchanabanthoeng A; Morand S; Jittapalapong S; Carcy B
[Ad] Address:1 Faculty of Veterinary Technology, Kasetsart University , Bangkok, Thailand .
[Ti] Title:Babesia Occurrence in Rodents in Relation to Landscapes of Mainland Southeast Asia.
[So] Source:Vector Borne Zoonotic Dis;18(3):121-130, 2018 Mar.
[Is] ISSN:1557-7759
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The purpose of this study is to investigate the relationships between habitat structure and Babesia spp. occurrence in rodents in mainland Southeast Asia. Of 1439 rodents and insectivores investigated, the protist Babesia was found in only 81 individuals (5.6% of the micromammals investigated) with Babesia microti U.S. type the more prevalent (4.1%), followed by the B. microti Kobe type (1.2%), and by the very rare Babesia BiCM002 (0.04%). We used georeferenced data of rodents analyzed for Babesia infection and land cover maps produced for the seven study sites in Thailand, Cambodia, and Lao PDR, where they were collected. Rodents infected by Babesia were more likely to be found in settlements close to forested areas, which may represent risky place for spillover of Babesia species to humans.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[St] Status:In-Data-Review
[do] DOI:10.1089/vbz.2017.2196

  10 / 4257 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29488237
[Au] Autor:Norgan AP; Juskewitch JE; Pritt BS; Winters JL
[Ad] Address:Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
[Ti] Title:The use of cytapheresis in the treatment of infectious diseases.
[So] Source:J Clin Apher;, 2018 Feb 28.
[Is] ISSN:1098-1101
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Cytapheresis (removal of cellular blood components) has been employed for treatment of infectious diseases since the 1960s. Techniques have included thrombocytapheresis (buffy coat apheresis) for loiasis, erythrocytapheresis for malaria and babesiosis, and leukocytapheresis for pertussis-associated lymphocytosis. Published data on these applications is largely limited to case level data and small observational studies; as such, recommendations for or against the use of cytapheresis in the treatment of infections have been extrapolated from these limited (and at times flawed) data sets. Consequently, utilization of cytapheresis in many instances is not uniform between institutions, and typically occurs at the discretion of treating medical teams. This review revisits the existing literature on the use of cytapheresis in the treatment of four infections (loasis, malaria, babesiosis, and pertussis) and examines the rationale underlying current treatment recommendations concerning its use.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180228
[Lr] Last revision date:180228
[St] Status:Publisher
[do] DOI:10.1002/jca.21620


page 1 of 426 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information